Scholar Rock Corrects Investor Call: FDA Requires Pregnancy Safety Study for Isembyld

summarizeSummary

Scholar Rock filed an 8-K correcting a statement made during its September 14 investor call. Management had said the FDA required no post-marketing safety commitments for Isembyld; in fact, the FDA is requiring a pregnancy safety study and fracture alert reports.

check_boxKey Events · Product Development and Regulatory · SRRK

• Management Statement Corrected

  During the September 14 investor call, management stated the FDA required no post-marketing safety commitments for Isembyld. This 8-K corrects that statement.

• Pregnancy Safety Study Required

  The FDA is requiring Scholar Rock to establish a pregnancy safety study to collect and analyze information on pregnancy complications and birth outcomes for exposed pregnancies.

• Fracture Alert Reports Required

  The FDA also requested that all serious and non-serious domestic and/or foreign cases of fractures be submitted as 15-day alert reports.

• Regulatory Burden Increases

  The post-marketing requirements add ongoing safety monitoring obligations beyond what was communicated to investors during the approval announcement.

auto_awesomeAnalysis · SRRK · Life Sciences

During the September 14 investor call celebrating FDA approval of Isembyld, management incorrectly stated the FDA required no post-marketing safety commitments. This 8-K corrects that: the FDA is requiring a pregnancy safety study and 15-day alert reports for fractures. The correction matters because it changes the post-approval regulatory burden and signals the FDA has specific safety concerns about bone and reproductive outcomes in SMA patients treated with apitegromab.